Navigation Links
One-Year European Registry Data Released for Popliteal Stenting With SUPERA®
Date:2/8/2011

w SUPERA is uniquely suited to the femoropopliteal anatomy, indicating it may indeed be a market-changing technology."

D. Christopher Metzger, M.D. is the Director of Cardiac and Peripheral Labs and Medical Director of Clinical Research at Wellmont CVA Heart Institute.  He is an investigator in the SUPERB trial, and also on faculty at LINC.  He remarked, "This data correlates well with our own experience with the SUPERA stent.  I believe we can now confidently stent, knowing that SUPERA will remain physiologically conformable, will not fracture, and will have excellent long-term patency.  In my opinion, future trials will confirm that the SUPERA stent will be an excellent front-line therapy for a majority of infra-inguinal endovascular interventions, especially in areas that have typically been a 'no-stent' zone."

Independent mechanical testing reported zero stent fractures for any SUPERA stent assessed after 10 million cycles of 120 degrees flexion and extension and 20 million cycles of torsion.  In comparison, all standard nitinol stents tested fractured before 100,000 cycles in the flexion and extension testing and before 1 million cycles in compression load testing.  The SUPERA stent was demonstrated to have a minimum of four times the radial strength and 360 percent stronger crush resistance than standard nitinol stents, and completely resisted fracturing, kinking, crushing, and crimping.

"The data from the Leipzig popliteal registry is very promising," observed Christopher Owens, President and CEO of IDEV.  "We are very excited about the feedback we are receiving from physicians who have direct experience with the SUPERA stent.  The fact that no other stent has been evaluated in the popliteal artery, let alone shown this level of patency, gives us confidence that it's truly a unique device in a growing market."

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is a
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohns Disease
6. Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
10. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
11. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Pa., Sept. 9 DeVilbiss Healthcare has selected Business ... the successful implementation of its Microsoft Dynamics AX solution. ... Sunrise Medical, DeVilbiss sought to select and implement a ... successful medical device manufacturer. The primary ...
... Sept. 9 Diplomat Specialty Pharmacy announced today they have earned ... ranking of the fastest-growing private companies in America. "We,re ... earning a position of 554 in the nation, but if you ... are even more remarkable," stated Phil Hagerman, President and CEO of ...
Cached Medicine Technology:Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare 2Diplomat Specialty Pharmacy Honored by Inc. Magazine as One of the Nation's Fastest-Growing Companies 2
(Date:7/11/2014)... 2014 The American Association of Poison ... centers are commending Senator Bill Nelson (D-FL) for his ... 2014 on July 10, 2014. Along with fellow Senate ... Commission (CPSC) to enact rules requiring safer, child-resistant packaging ... , Senate co-sponsors of the bill include: Sen. Richard ...
(Date:7/11/2014)... 2014 As transvaginal mesh lawsuits ... & Johnson’s Ethicon Inc. unit continue to mount ... the Texas Attorney General’s Office has acknowledged that ... mesh products used to treat pelvic organ prolapse ... from kens5.com, the probe began nearly two years ...
(Date:7/11/2014)... News) -- People with the lowest incomes may have a ... (PAD), a new study suggests. People with PAD have ... most often the legs. The condition causes leg pain and ... the body. People with PAD have a higher risk for ... 6,800 people with PAD who took part in the U.S. ...
(Date:7/11/2014)... 2014 Microbiology testing is a highly ... industry, which is expected to pose the biggest challenge ... owes its growth to the ongoing spread of AIDS ... and a major factor leading to the upsurge of ... and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and ... and revenue forecast. The well intervention services market in Europe ... to $3.4 billion by 2018, at a CAGR of 7% ... the Europe Well Intervention Market report, to get an idea ... of the segmentation in the Europe well intervention market, and ...
Breaking Medicine News(10 mins):Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Poor More Prone to Leg Circulation Trouble 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3
... testing breast tumors for HER2 ( http://www.mayoclinic.com/health/breast-cancer/AN00495 ) proteins ... of tumor (a single tumor block) is analyzed. However, ... ( http://www.mayoclinic.org/ ) found that HER2 results can vary ... tumor blocks are analyzed. This could have significant ...
... News) -- Americans who live in walkable neighborhoods are ... a higher quality of life, a new study suggests. ... stroll to such destinations as parks and playgrounds, club ... coffee shops and restaurants, explained study author Shannon Rogers ...
... from a specialized scan, radiation oncologists at Mayo Clinic ... number of lymph nodes critical for removing fluid from ... VIDEO ALERT: Additional audio and video resources, including excerpts ... researchers presenting at San Antonio Breast Cancer Symposium, are ...
... GeparQuinto study, randomized Phase III efficacy data on the ... early breast cancer will be presented at the 33rd ... von Minckwitz, M.D., Ph.D., managing director of the German ... efficacy data from this study, which will detail the ...
... Dec. 10 (HealthDay News) -- Children and teens accounted for ... treated in U.S. emergency departments between 1997 and 2006, a ... such heat-related injuries also increased 133 percent during the study ... according to the researchers at the Center for Injury Research ...
... of circulating tumor cells (CTCs) cells that have detached ... the blood are an independent prognostic marker in metastatic ... CTC level during therapy was found to be an early ... series validating the prognostic value of CTCs in first-line chemotherapy ...
Cached Medicine News:Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 2Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 3Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 4Health News:'Walkable' Communities More Close-Knit, Study Finds 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 3Health News:Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented 2Health News:Children, Teens Account for Half of Exercise-Related Heat Injuries 2Health News:High CTC levels predicted poor outcome in metastatic breast cancer 2
Sub Pectoral Bra...
Bandeau Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test ... Ischemia Modified Albumin (IMA®) by measuring the ... patient serum sample. First identified in the ... albumin comes in contact with ischemic tissue ...
Medicine Products: